Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas

The aim of this study to determine whether the aberrant N-glycosylated serum immunoglobulins (Igs) can be applied as a diagnostic marker of urothelial carcinoma (UC). Between 2009 and 2016, we randomly obtained serum available from 237 UC and also 96 prostate cancer as other cancer controls from our serum bank and also obtained—from 339 healthy volunteers (HV)—controls obtained from community-dwelling volunteers in Iwaki Health Promotion Project. A total of 32 types of N-glycan levels on Igs were determined by high-throughput N-glycomics and analyzed by multivariable discriminant analysis. We found five UC-associated aberrant N-glycans changes on Igs and also found that asialo-bisecting GlcNAc type N-glycan on Igs were significantly accumulated in UC patients. The diagnostic N-glycan Score (dNGScore) established by combination of five N-glycans on Igs discriminated UC patients from HV and prostate cancer (PC) patients with 92.8% sensitivity and 97.2% specificity. The area under the curve (AUC) for of the dNGScore was 0.969 for UC detection that was much superior to that of urine cytology (AUC, 0.707) and hematuria (AUC, 0.892). Furthermore, dNGScore can detect hematuria and urine cytology negative patients. The dNGscore based on aberrant N-glycosylation signatures of Igs were found to be promising diagnostic biomarkers of UCs.

[1]  Y. Mechref,et al.  Glycosylation Changes in Brain Cancer. , 2017, ACS chemical neuroscience.

[2]  T. Funyu,et al.  Clinical relevance of aortic calcification in urolithiasis patients , 2017, BMC Urology.

[3]  T. Habuchi,et al.  Clinical implications of serum N‐glycan profiling as a diagnostic and prognostic biomarker in germ‐cell tumors , 2017, Cancer medicine.

[4]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[5]  T. Kaneko,et al.  Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer , 2017, International journal of molecular sciences.

[6]  T. Habuchi,et al.  Significance of Serum N-glycan Profiling as a Diagnostic Biomarker in Urothelial Carcinoma. , 2016, European urology focus.

[7]  S. Brouard,et al.  Sialylation of antibodies in kidney recipients with de novo donor specific antibody, with or without antibody mediated rejection. , 2016, Human immunology.

[8]  Jun Yao,et al.  Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity , 2016, Nature Communications.

[9]  Holger Moch,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. , 2016, European urology.

[10]  Pauline M. Rudd,et al.  Glycosylation of plasma IgG in colorectal cancer prognosis , 2016, Scientific Reports.

[11]  Rajesh C. Dash,et al.  The diagnostic accuracy of urine-based tests for bladder cancer varies greatly by patient , 2016, BMC Urology.

[12]  Dan Zhang,et al.  Disease-specific IgG Fc N-glycosylation as personalized biomarkers to differentiate gastric cancer from benign gastric diseases , 2016, Scientific Reports.

[13]  K. Murayama,et al.  Glycosylation status of serum immunoglobulin G in patients with prostate diseases , 2016, Cancer medicine.

[14]  L. McDonnell,et al.  Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid , 2015, Journal of Neuroinflammation.

[15]  L. Joshi,et al.  Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics , 2015, BioMed research international.

[16]  David M. Rocke,et al.  The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer. , 2015, EuPA open proteomics.

[17]  T. Habuchi,et al.  Serum tri‐ and tetra‐antennary N‐glycan is a potential predictive biomarker for castration‐resistant prostate cancer , 2014, The Prostate.

[18]  Yusuke Suzuki,et al.  Diagnosis and activity assessment of immunoglobulin A nephropathy: current perspectives on noninvasive testing with aberrantly glycosylated immunoglobulin A-related biomarkers , 2014, International journal of nephrology and renovascular disease.

[19]  T. Habuchi,et al.  Serum N-glycan alteration associated with renal cell carcinoma detected by high throughput glycan analysis. , 2014, The Journal of urology.

[20]  M. Tsushima,et al.  Serum N-Glycan Profiling Predicts Prognosis in Patients Undergoing Hemodialysis , 2013, TheScientificWorldJournal.

[21]  N. Masumori,et al.  N- and O-glycome analysis of serum and urine from bladder cancer patients using a high-throughput glycoblotting method , 2013 .

[22]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[23]  H. Shiraha,et al.  Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer , 2013, Journal of Gastroenterology.

[24]  N. Cowan.  CT urography for hematuria , 2012, Nature Reviews Urology.

[25]  L. Lacombe,et al.  Carcinoma of the upper urinary tract , 2009, Cancer.

[26]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[27]  Derek Christie,et al.  Resampling with Excel , 2004 .

[28]  L. Ellison,et al.  Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. , 2000, The Journal of urology.

[29]  D J O'Kane,et al.  Comparison of screening methods in the detection of bladder cancer. , 1999, The Journal of urology.

[30]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[31]  S. Elliott,et al.  The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer , 2018, The Journal of urology.

[32]  M. Quek,et al.  The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology , 2016, Acta Cytologica.

[33]  N. Hahn,et al.  Bladder cancer: a disease ripe for major advances. , 2014, Clinical advances in hematology & oncology : H&O.

[34]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[35]  R. Dwek,et al.  The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis , 2005, Springer Seminars in Immunopathology.

[36]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[37]  N. Dubrawsky.  Cancer statistics , 2022 .